A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

21 Jun 2021 Results from two Phase 2 clinical studies (SPR001-201 and SPR001-202) presented in the Journal of Clinical Endocrinology and Metabolism.
21 Jun 2021 Results published in Spruce Biosciences Media Release.
19 Jun 2021 Results post hoc analyses from two open-label Phase 2 clinical trials (SPR001-201 and SPR001-202) assessing the safety and efficacy of tildacerfont in adult participants with 21OHD, published in the Journal of Clinical Endocrinology and Metabolism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com